The project is an observational, prospective study. Its aim is to deepen ourunderstanding of COVID-19 in older patients hospitalized and diagnosed with COVID-19.In particular, socioeconomic, diagnostic, biological, functional, therapy data will becollected at the patients' admission, during hospital stay, at the discharge and 1, 3, 6,12 months after discharge.Results and findings will help support changes in clinical practice and decision making,with the aim to reduce the use of healthcare services and the healthcare expenditure.

The goal of the research is to assess candidate COVID-19 rapid diagnostic tests (e.g.immunodiagnostic antibody tests, like Cellex qSARS-CoV-2 IgG/IgM Rapid Test, or antigentests, like Turklab Test-It COVID-19 Home Test, AllBio Science Inc. and ArtronLaboratories Inc. rapid COVID-19 antigen tests in order to judge their clinical accuracycompared to Centers for Disease Control (CDC)-recommended molecular genetic testing andclinical diagnosis. Second, it is our goal to determine if self-testing assisted byCOVIDscanDX mobile device camera acquisition software platform and telemedicineclinical/technical support (virtual point-of-care) improves the ease of use and immediateinterpretation of the tests, thus making self-testing comparable in accuracy and safetyto testing in a clinical setting. Third, we are testing antibodies to SARS-CoV-2 afterdiagnosis with COVID-19 or following vaccination to measure the onset and time course ofdetectable antibodies from finger-stick blood drops and rapid antibody lateral flowtests. The overall purpose of the study is to dramatically increase the capacity ofCOVID-19 testing by establishing the safety, ease-of-use and validity of self-testingassisted by mobile device imaging and telemedicine remote support and provide evidence ofantibody time-course response to vaccination.

The study aims to investigate the efficacy of extracorporeal CO2 removal for correctionof hypercapnia in coronavirus disease 19 (COVID-19)-associated acute respiratory distresssyndrome

The overall objective of this project is to develop an emergent treatment protocol usingadoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis isthat SARS-CoV-2 specific T cells from convalescent donors who have recovered fromCOVID-19 can be manufactured expeditiously for the treatment of severe SARS-CoV-2infections.

Efficacy of Ivermectin in larger doses in COVID-19 treatment

The study investigators are interested in learning more about how drugs, that are givento children by their health care provider, act in the bodies of children and young adultsin hopes to find the most safe and effective dose for children. The primary objective ofthis study is to evaluate the PK of understudied drugs currently being administered tochildren per SOC as prescribed by their treating provider.

The primary objective of this research study is to assess Radiation Oncology healthcareproviders (i.e. faculty, residents and advanced practice providers (APPs) implementationand perception of telehealth for on treatment patients in lieu of in person on treatmentvisits during standard of care radiotherapy during COVID-19.

CORIA is an observational cohort study of immunosuppressed populations who test positivefor COVID-19. This includes people living with HIV, cancer, acquired immunodeficiencyassociated with other immunosuppressive therapy, primary immunodeficiency and recipientsof a solid organ transplant. Participants will have routine clinical data collected withoptional baseline collection and storage of a blood sample for storage . The study willbe conducted in up to 30 sites within Australia.

In this study we will collect granular information on cancer patients infected withCOVID-19, as rapidly as possible. The mechanism for collection of this information is ade-identified centralized registry housed at Vanderbilt University Medical Center, withdata donations from internal and external health care professionals.

Since the outbreak of a syndrome of acute respiratory distress associated to a novelcoronavirus 2 (SARS-Cov2) that began in China, Europe and France have to face a sanitaryemergency with critically care support when the patient evolves to an acute respiratorydistress (ARDS). In the context of supply shortages (ventilators, bed capacities) thatcountries have to deal with, data were lacking of characteristics and outcomes ofpatients admitted to intensive care unit (ICU). the purpose of this project is to reportthe epidemiology and the outcomes of a French cohort of critically ill patients withSARS-Cov2